City A.M.
•
02/23/2026
•
Free
Prothena reported substantial cash usage in 2025 with $163.7 million spent on operations and investments, maintains a strong cash position of $308.4 m...
Read Full Article →
CNBC Business
•
02/18/2026
•
Free
The FDA's decision to review Moderna’s mRNA flu vaccine application could impact the company’s revenue by potentially enabling sales during the upcomi...
Read Full Article →
CNBC Business
•
02/13/2026
•
Free
Lilly’s accumulation of GLP-1 weight loss pills prior to FDA approval indicates strategic preparation for potential high demand, which could significa...
Read Full Article →
CNBC Business
•
02/10/2026
•
Free
The FDA's refusal to review Moderna's mRNA-1010 application may delay the company's potential revenue growth from the experimental flu shot and impact...
Read Full Article →
CNBC Business
•
02/09/2026
•
Free
The FDA's request to halt misleading advertisements may impact Novo Nordisk's marketing strategy and potentially affect the sales performance of its o...
Read Full Article →
City A.M.
•
01/05/2026
•
Free
Helus Pharma’s listing on major stock exchanges enhances its ability to secure capital and advance its pipeline, supporting the commercialization of i...
Read Full Article →
CNBC Business
•
01/01/2026
•
Free
The FDA's approval of Wegovy underscores critical challenges and opportunities Novo Nordisk must navigate in the U.S. market, impacting its financial...
Read Full Article →
CNBC Business
•
12/23/2025
•
Free
The FDA’s approval of Novo Nordisk’s new GLP-1 pill is expected to positively impact the company’s market value and investor confidence due to its pot...
Read Full Article →
CNBC Business
•
12/22/2025
•
Free
The FDA’s approval of Novo Nordisk’s oral GLP-1 medication for obesity provides the company a competitive advantage in the growing weight-loss drug ma...
Read Full Article →
CNBC Business
•
12/15/2025
•
Free
During the government shutdown, the agency allocated a substantial budget to fund an overseas conference for multiple employees, highlighting concerns...
Read Full Article →
Investopedia
•
12/01/2025
•
Free
The anticipated regulatory changes regarding vaccine approvals are expected to influence market performance and investor confidence in companies invol...
Read Full Article →
City A.M.
•
11/06/2025
•
Free
Prothena reported substantial cash outflows totaling $140.4 million in the first nine months of 2025, maintaining a strong cash position of $331.7 mil...
Read Full Article →
City A.M.
•
11/04/2025
•
Free
The company’s strengthened cash reserves and progress in regulatory discussions enable an expedited commercialization timeline, potentially enhancing...
Read Full Article →
CNBC Business
•
10/29/2025
•
Free
Accelerating the approval process for biosimilar medications may reduce expenses for consumers while potentially impacting the revenue streams of esta...
Read Full Article →
CNBC Business
•
09/10/2025
•
Free
The FDA’s recent regulations targeting compounded GLP-1 medications could impact market dynamics, while Apple’s introduction of enhanced health featur...
Read Full Article →
CNBC Business
•
08/27/2025
•
Free
The recent authorization of updated Covid vaccines may influence insurance coverage policies and affect the availability of these shots for individual...
Read Full Article →
The Guardian – Business
•
08/20/2025
•
Free
The recall of frozen shrimp due to radioactive contamination may lead to significant financial losses for the retailer, impacting sales, supply chain...
Read Full Article →
Investopedia
•
07/29/2025
•
Free
The approval to restart Elevidys sales has notably impacted Sarepta Therapeutics' market value, reflecting investor confidence and a positive shift in...
Read Full Article →
Investopedia
•
07/21/2025
•
Free
The company’s shares declined further after it declined the regulatory agency’s request to remove its medication from the market, raising concerns abo...
Read Full Article →
CNBC Business
•
07/11/2025
•
Free
The FDA’s new approach to factoring in drug affordability during voucher issuance may influence the overall cost dynamics and market access for medica...
Read Full Article →
CNBC Business
•
06/18/2025
•
Free
The approval of Gilead’s biannual HIV prevention injection presents a significant development in treatment options, though its impact may be influence...
Read Full Article →
Investopedia
•
06/13/2025
•
Free
The recent FDA authorization to broaden the application of Merck's leading medication could potentially increase the company's revenue by accessing ne...
Read Full Article →
CNBC Business
•
06/09/2025
•
Free
Merck’s newly authorized RSV vaccine for infants is expected to impact the market by challenging established treatments, potentially influencing sales...
Read Full Article →
Investopedia
•
06/02/2025
•
Free
The approval of Moderna's latest COVID-19 vaccine by the FDA has positively influenced investor confidence, leading to a notable rise in the company's...
Read Full Article →
CNBC Business
•
05/20/2025
•
Free
The FDA’s conditional approval of Novavax’s Covid-19 vaccine, despite limitations, may influence the company’s market performance and future revenue p...
Read Full Article →
Investopedia
•
05/20/2025
•
Free
The announcement of updated FDA recommendations for COVID-19 boosters led to a notable increase in Moderna’s share value, reflecting investor optimism...
Read Full Article →
Cointelegraph
•
04/30/2025
•
Free
The implementation of self-sovereign identity technology is proposed as a more effective solution than the EU's digital product passports to combat fo...
Read Full Article →
